NCT06123026

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Northwestern University · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Conditions

• Lactation Suppressed
• Second Trimester Abortion

Interventions

Type	Name	Description
DRUG	Cabergoline	1mg oral cabergoline given to participants once
DRUG	Placebo	1 encapsulated placebo tablet given to participants after procedure

Timeline

• Start date: 2023-12-18
• Primary completion: 2024-06-30
• Completion: 2024-06-30
• First posted: 2023-11-08
• Last updated: 2024-05-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study